Scaffold Protein

Scaffold Proteins are specialised molecules that organise signalling complexes by providing binding platforms for multiple pathway components, controlling signal transduction specificity, efficiency, and spatial organisation within cells. These organisational proteins contain multiple binding domains that simultaneously interact with various signalling molecules, creating physical proximity that enhances reaction rates and prevents signal diffusion. Classic examples include kinase suppressor of Ras (KSR), which scaffolds the MAP kinase cascade, and A-kinase anchoring proteins (AKAPs).

Understanding scaffold protein function offers pharmaceutical opportunities for pathway-selective intervention. Rather than inhibiting enzymes that participate in multiple pathways and potentially causing broad toxicity, disrupting scaffold interactions can selectively block specific signalling outputs. Small molecules and peptides targeting scaffold binding interfaces represent an emerging drug class, with several candidates entering clinical development for oncology and inflammatory indications. The biopharmaceutical industry increasingly recognises scaffold proteins as druggable targets, particularly for pathways where direct enzyme inhibition has proven challenging or produced unacceptable side effects. Advanced structural biology and fragment-based drug discovery approaches enable identification of compounds that disrupt protein-protein interactions at scaffold binding surfaces, presenting expanding opportunities for therapeutic intervention.